Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C94214
http://purl.obolibrary.org/obo/NCIT_C94214
|
|---|---|
| Preferred Name | Alpelisib |
| Definitions |
An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally bioavailable phosphatidylinositol 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Alpelisib specifically inhibits PI3K in the PI3K/AKT kinase (or protein kinase B) signaling pathway, thereby inhibiting the activation of the PI3K signaling pathway. This may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations. Activation of the PI3K signaling pathway is frequently associated with tumorigenesis. Dysregulated PI3K signaling may contribute to tumor resistance to a variety of antineoplastic agents. |
|---|---|
| prefLabel | Alpelisib
|
| label | Alpelisib
|
| PDQ_Closed_Trial_Search_ID | 687431
|
| code | C94214
|
| Has_Target | |
| prefixIRI | NCIT:C94214
|
| in_subset |
See more
See less
|
| Display_Name | Alpelisib
|
| Preferred_Name | Alpelisib
|
| FDA_UNII_Code | 08W5N2C97Q
|
| Contributing_Source |
CTRP
FDA
|
| Maps_To | Alpelisib
|
| CAS_Registry | 1217486-61-7
|
| NCI_Drug_Dictionary_ID | 687431
|
| type | |
| Is_Value_For_GDC_Property | |
| subClassOf | |
| PDQ_Open_Trial_Search_ID | 687431
|
| Accepted_Therapeutic_Use_For | hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer
f adult and pediatric patients 2 years of age and older with severe manifestations of PIK3CARelated Overgrowth Spectrum (PROS) who require systemic therapy.
|
| Semantic_Type | Pharmacologic Substance
|
| UMLS_CUI | C2986399
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |